^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cytarabine

    i
    Other names: HiDAC, LDAC
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    Related drugs:
    1d
    Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=40, Completed, Wake Forest University Health Sciences | Unknown status --> Completed | Phase classification: P2 --> P1
    Trial completion • Phase classification
    |
    cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)
    5d
    VITAL: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Apr 2024 --> Sep 2024
    Trial completion date • Combination therapy • Tumor mutational burden
    |
    SRC (SRC Proto-Oncogene)
    |
    cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)
    6d
    DFCI 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (clinicaltrials.gov)
    P3, N=560, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Nov 2028 --> Nov 2034
    Trial completion date
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • dexrazoxane
    7d
    Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients (clinicaltrials.gov)
    P2, N=60, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    7d
    Gossypol acetic acid regulates leukemia stem cells by degrading LRPPRC via inhibiting IL-6/JAK1/STAT3 signaling or resulting mitochondrial dysfunction. (PubMed, World J Stem Cells)
    Taken together, the results indicate that GAA might overcome the BMM protective effect and be considered as a novel and effective combination therapy for AML.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • CD38 (CD38 Molecule) • JAK1 (Janus Kinase 1) • CD34 (CD34 molecule) • FOXM1 (Forkhead Box M1) • LRPPRC (Leucine Rich Pentatricopeptide Repeat Containing)
    |
    cytarabine • R-(-)-gossypol (AT 101)
    8d
    Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) (clinicaltrials.gov)
    P2, N=145, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • dasatinib • cytarabine • bortezomib • cyclophosphamide • vincristine • daunorubicin • nelarabine • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine
    8d
    IDHENTIFY: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (clinicaltrials.gov)
    P3, N=319, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation
    |
    Abbott RealTime IDH2
    |
    cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea
    8d
    Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov)
    P2, N=137, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024
    Trial completion • Trial completion date • Combination therapy
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Xalkori (crizotinib) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • Adcetris (brentuximab vedotin) • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    8d
    Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients (clinicaltrials.gov)
    P2, N=100, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    cytarabine • Xpovio (selinexor) • daunorubicin • Starasid (cytarabine ocfosfate)
    8d
    CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma (clinicaltrials.gov)
    P1, N=49, Completed, Wake Forest University Health Sciences | Phase classification: P2 --> P1
    Phase classification
    |
    cytarabine • mitoxantrone • Bylantra (devimistat) • Starasid (cytarabine ocfosfate)
    8d
    Increased Th17 and Treg levels in peripheral blood positively correlate with minimal residual disease in acute myeloid leukaemia. (PubMed, Hematology)
    Changes in Th17 and Treg cells in the peripheral blood of 32 patients with ND AML were observed before and after induction chemotherapy with cytarabine for seven days and anthracycline for three days...The frequencies of Tregs and Th17 cells positively correlated with MRD onset. Increased Th17 and Treg cell levels were positively correlated with onset of AML, poor remission, and MRD.
    Journal • Minimal residual disease
    |
    IL6 (Interleukin 6) • IL10 (Interleukin 10) • CSF2 (Colony stimulating factor 2) • IL17A (Interleukin 17A)
    |
    cytarabine
    9d
    Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=66, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: May 2028 --> May 2025
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    CD20 expression • CD22 positive
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • mercaptopurine • dexamethasone injection
    9d
    Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL (clinicaltrials.gov)
    P3, N=81, Recruiting, First Affiliated Hospital of Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • daunorubicin • Synribo (omacetaxine mepesuccinate) • vindesine
    9d
    GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy. (PubMed, Ann Hematol)
    CCND1, CD44 and PROM1 were potential target genes differentially regulated by GLI1 rs2229300. Our results demonstrated for the first time that GLI1 polymorphisms influence chemosensitivity and prognosis of young de novo AML patients treated with Ara-C.
    Journal
    |
    CCND1 (Cyclin D1) • GLI1 (GLI Family Zinc Finger 1) • PROM1 (Prominin 1)
    |
    cytarabine
    10d
    Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma. (PubMed, Hematol Oncol)
    The HD-AraC (high-dose cytarabine) regimen was the main first-line induction regimen for younger HBsAg+ patients, and cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) were used for elderly patients. HBsAg seropositivity was associated with a significantly shorter PFS than HBsAg seronegativity when patients were treated with rituximab or CHOP-based regimens...Among the 74 patients who underwent targeted deep sequencing (TDS), the nonsynonymous mutation load of HBsAg+ MCL patients was greater than that of HBsAg- MCL patients. HDAC1, TRAF5, FGFR4, SMAD2, JAK3, SMC1A, ZAP70, BLM, CDK12, PLCG2, SMO, TP63, NF1, PTPR, EPHA2, RPTOR and FIP1L1 were significantly enriched in HBsAg+ MCL patients.
    Clinical data • Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • NF1 (Neurofibromin 1) • FGFR4 (Fibroblast growth factor receptor 4) • CDK12 (Cyclin dependent kinase 12) • PLCG2 (Phospholipase C Gamma 2) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1) • JAK3 (Janus Kinase 3) • HDAC1 (Histone Deacetylase 1) • TP63 (Tumor protein 63) • SMAD2 (SMAD Family Member 2) • SMC1A (Structural Maintenance Of Chromosomes 1A)
    |
    BLM mutation • JAK3 mutation
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine
    12d
    Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL (clinicaltrials.gov)
    P2, N=53, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • mercaptopurine
    12d
    A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia (clinicaltrials.gov)
    P3, N=316, Not yet recruiting, Hutchmed
    New P3 trial
    |
    cytarabine • azacitidine • HMPL-306
    13d
    Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (clinicaltrials.gov)
    P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024
    Trial initiation date • Combination therapy
    |
    MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (recombinant Erwinia asparaginase) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    13d
    Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov)
    P2, N=154, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Aug 2024
    Trial initiation date
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • navitoclax (ABT 263) • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    13d
    A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=97, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Sep 2026 --> Jul 2031 | Trial primary completion date: Nov 2024 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    cytarabine • Xospata (gilteritinib) • fludarabine IV
    13d
    Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis. (PubMed, BMC Cancer)
    Acute myeloid leukaemia (AML) is a fatal haematopoietic malignancy and is treated with the conventional combination of cytarabine (Ara-C) and daunorubicin (Dau). HHT synergistically induces apoptosis in combination with Ara-C in vitro and prolongs the survival of xenografts. We provide a new mechanism for AML treatment by regulating the p38 MAPK/H2AX/Mcl-1 axis to improve cytarabine therapy.
    Journal
    |
    MCL1 (Myeloid cell leukemia 1)
    |
    cytarabine • daunorubicin • Synribo (omacetaxine mepesuccinate)
    13d
    A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P3, N=680, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024
    Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CD19 (CD19 Molecule) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CSF1R (Colony stimulating factor 1 receptor)
    |
    CD19 expression
    |
    TruSight RNA Pan-Cancer Panel
    |
    dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)
    15d
    Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=41, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • cytarabine • etoposide IV • mitoxantrone
    16d
    MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Masonic Cancer Center, University of Minnesota
    New P2 trial
    |
    Keytruda (pembrolizumab) • cytarabine • etoposide IV • carmustine • melphalan
    19d
    Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • methotrexate • revumenib (SNDX-5613)
    19d
    Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, LLS PedAL Initiative, LLC
    New P1 trial • Combination therapy
    |
    cytarabine • ziftomenib (KO-539) • fludarabine IV
    20d
    Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3, N=310, Suspended, Alliance for Clinical Trials in Oncology | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule) • ITGB1 (Integrin Subunit Beta 1)
    |
    CD20 positive • CD22 positive
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine
    20d
    Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Nantes University Hospital | Trial completion date: Nov 2025 --> Jan 2028 | Trial primary completion date: Nov 2025 --> Jan 2028
    Trial completion date • Trial primary completion date • Combination therapy
    |
    cytarabine • Darzalex (daratumumab) • idarubicin hydrochloride
    21d
    ALL Adult Consortium Trial: Adult ALL Trial (clinicaltrials.gov)
    P2, N=112, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine
    21d
    Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=130, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1
    Enrollment closed • Phase classification • Combination therapy
    |
    cytarabine • cyclophosphamide • vincristine • daunorubicin • carfilzomib • mitoxantrone • Oncaspar liquid (pegaspargase) • mercaptopurine • dexamethasone injection
    21d
    A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1. (PubMed, Cells)
    Adjuvant treatment for Glioblastoma Grade 4 with Temozolomide (TMZ) inevitably fails due to therapeutic resistance, necessitating new approaches...We assessed TMZ, Methotrexate (MTX), and Cytarabine (Ara-C) (apoptosis inducers) combined with XPO1/Bcl-2/Mcl-1-inhibitors (apoptosis rescue) in GB cell lines and primary GB stem-like cells (GSCs)...TMZ, MTX, and Ara-C combined with E, V, and A evidenced highly lethal effects when combined. As no significant cell death induction in mouse brain slices was observed, we conclude that this drug combination is effective in vitro and expected to have low side effects in vivo.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • CASP3 (Caspase 3)
    |
    Venclexta (venetoclax) • temozolomide • cytarabine • methotrexate • eltanexor (KPT-8602)
    22d
    Effects of nucleoside analogues, lipophilic prodrugs and elaidic acids on core signaling pathways in cancer cells. (PubMed, Nucleosides Nucleotides Nucleic Acids)
    Nucleoside analogs such as gemcitabine (GEM; dFdC) and cytarabine (Ara-C) require nucleoside transporters to enter cells, and deficiency in equilibrative nucleoside transporter 1 (ENT1) can lead to resistance to these drugs. In A549 cells treatment with Ara-C, CP-4055 and EA-4126 decreased the p-P38/P38 after 6 hr. The findings suggest that both parent drugs, prodrugs, and the EA chain influence cell survival and signaling pathways.
    Journal
    |
    SLC29A1 (Solute Carrier Family 29 Member 1)
    |
    gemcitabine • cytarabine
    23d
    ENHANCE-2: Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated (clinicaltrials.gov)
    P3, N=258, Terminated, Gilead Sciences | Active, not recruiting --> Terminated; Study discontinued due to futility.
    Trial termination • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • magrolimab (GS-4721)
    24d
    FLAG/FLAG-Ida Regimen in Secondary and Relapsed/Refractory Acute Myeloid Leukemia-Even in the Era of New Treatment Modalities Still a Significant Player. (PubMed, J Clin Med)
    The aim of the study was to assess the efficacy and toxicity of fludarabine, cytarabine, and granulocyte-colony stimulation factor (FLAG) with or without idarubicin (-Ida) and to discuss novel therapies in this setting. Among the variables, including age, FLT3 mutation status, European LeukemiaNet (ELN) 2022 classification risk, FLAG vs. FLAG-Ida, and aHSCT, a multivariate analysis revealed that only aHSCT significantly influenced overall survival. (4) FLAG(-Ida) chemotherapy remains an effective salvage chemotherapy for patients with r/r and secondary AML with a plan of proceeding to aHSCT.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    cytarabine • idarubicin hydrochloride • fludarabine IV
    26d
    Next-generation sequencing reveals relapse and leukemia-free survival risks in newly diagnosed acute myeloid leukemia treated with CAG regimen combined with decitabine. (PubMed, Cancer Pathog Ther)
    Decitabine, a deoxyribonucleic acid (DNA) methyltransferase (DNMT) inhibitor, combined with cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor (DCAG), has been used in patients newly diagnosed with AML. NGS demonstrated a dismal overall outcome in patients with the rare PTPN11 mutations, indicating the need for new therapies that target this high-risk subtype of AML. These results offer a potential molecular stratification and treatment guidance for patients with AML.
    Journal • Next-generation sequencing
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • GATA2 (GATA Binding Protein 2)
    |
    FLT3-ITD mutation • IDH1 mutation • PTPN11 mutation
    |
    cytarabine • decitabine • aclarubicin
    27d
    A Phase III Study Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL (clinicaltrials.gov)
    P3, N=81, Not yet recruiting, First Affiliated Hospital of Zhejiang University
    New P3 trial
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • daunorubicin • Synribo (omacetaxine mepesuccinate) • vindesine
    28d
    Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Tianjin Medical University General Hospital | Initiation date: Mar 2024 --> Dec 2024
    Trial initiation date
    |
    cytarabine • cyclophosphamide
    29d
    Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=32, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Aug 2024 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • GATA2 (GATA Binding Protein 2) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • DEK (DEK Proto-Oncogene) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation
    |
    cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)
    29d
    VA vs DA for Newly Diagnosed Hig-risk AML (clinicaltrials.gov)
    P2/3, N=116, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Jul 2027 --> Oct 2027 | Initiation date: Jul 2023 --> Apr 2024 | Trial primary completion date: Jul 2025 --> Oct 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin
    29d
    NKX101-101: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Nkarta Inc. | Recruiting --> Active, not recruiting | N=90 --> 61
    Enrollment closed • Enrollment change
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    cytarabine • cyclophosphamide • decitabine • fludarabine IV • NKX101
    30d
    Veno-venous extracorporeal membrane oxygenation for capillary leak syndrome during induction chemotherapy in acute myeloid leukemia (PubMed, Rinsho Ketsueki)
    A 44-year-old woman was diagnosed with acute myeloid leukemia (RUNX1::RUNX1T1 translocation) and received induction chemotherapy with idarubicin hydrochloride and cytosine arabinoside. The patient received consolidation chemotherapy, and has maintained complete remission. Severe respiratory failure during induction chemotherapy for acute leukemia can be fatal, but VV-ECMO may be lifesaving.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
    |
    cytarabine • idarubicin hydrochloride
    30d
    A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=7, Terminated, Sanofi | Trial completion date: Jan 2025 --> Mar 2024 | Active, not recruiting --> Terminated; Sponsor's decision
    Trial completion date • Trial termination
    |
    cytarabine • fludarabine IV • SAR445419